Doloteffin – with Devil's claw
A natural way to effectively support treatment of degenerative disorders of the locomotor system.
Why to take Doloteffin – instead of other products ?
Devil's claw in Doloteffin has several advantages and benefits:
Efficacy:
- Clinical efficacy has been known for many years.
- relieves pain in degenerative rheumatic conditions: Patients who took watery extract of devil's claw had as much pain relief as patients who took a chemical defined antiinflammatory medication 1
- antiinflammatory action (in vitro) 2
Tolerability:
- clearly better tolerated compared to synthetic pain killers 1
- No known drug interactions associated with Doloteffin, meaning, Doloteffin can be combined with other pain medications.
- The supportive therapy with Devils claw can help to minimize side effects and to strengthen patient's health.
- Due to the excellent safety profile of Doloteffin, it can also be used to support long-term treatment.
![](/fileadmin/Demo/CONTENT/doloteffin-aqueous-extract-devils-claw_CT.jpg)
The particular feature of Doloteffin:
Aqueous extract of the root of Devil's claw
- In contrast to alcoholic extracts, aqueous extracts of Devil’s claw as in Doloteffin lead to specific lowering of a central inflammatory mediator (Interleukin Il-1 beta). 3
Established Phytopharmaceutical
Doloteffin is a modern medicinal plant product. It is designated to combine the broad clinical experiences of a traditional used medicinal plant with a contemporary GMP-conform presented outstanding product, therefore meeting highly established product standards of safety and quality. Doloteffin is manufactured in Germany.
- monograph conform
- corresponds to the WHO and EMEA GACP guidelines* for medicinal plants and starting materials of herbal origin
- proven efficacy in clinically controlled trials
- lactose-free
* WHO guidelines on good agricultural and collection practices for medicinal plants.
EMEA guideline on good agricultural and collection practices (GACP) for starting materials of herbal origin.
![](/fileadmin/Demo/CONTENT/trennlinie-3px-gruen.png)
1. Chrubasik et al., 2003
2. Tippler et al., 1996
3. Fiebich et al., 2001; Chrubasik et al., 2002
![](/fileadmin/Demo/CONTENT/trennlinie-3px-gruen.png)